Intellia shareholders elect three Class III directors and approve 2025 equity plan

Intellia Therapeutics, Inc.

Elected William Chase, Georgia Keresty, and John M. Leonard as Class III directors for three-year terms ending 2028.
Approved the 2025 Equity Incentive Plan: 50.8M for, 13.6M against, 93.8K abstentions.
Ratified Deloitte & Touche as independent auditor for FY2025: 82.1M for, 497.8K against.
Advisory say-on-pay vote passed (45.8M for, 18.6M against); future votes will be held annually.
Broker non-votes were 18.3M on director elections, equity plan, and say-on-pay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.